Flagship Biotech International Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Flagship Biotech International Private Limited Pharmaceutical Export Portfolio Dataset — 4 Products, $429.3K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Flagship Biotech International Private Limited — Pharmaceutical Exporter Profile (2026) | 4 Products, $429.3K Trade | TransData Nexus

Flagship Biotech International Private Limited

Indian Pharmaceutical Exporter · Advanced Antibiotics Specialist · $429.3K Total Trade · DGFT Verified

Flagship Biotech International Private Limited is an Indian pharmaceutical exporter with a total trade value of $429.3K across 4 products in 4 therapeutic categories. Based on 23 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Teicoplanin ($250.0K), Levamisole ($75.0K), Antitoxin ($53.7K).

Flagship Biotech International Private Limited — Export Portfolio & Destination Treemap

Flagship Biotech International Private Limited pharmaceutical export portfolio — 4 products across 4 therapeutic categories. Source: Indian Customs (DGFT).

Who is Flagship Biotech International Private Limited? — Company Overview & Market Position

Flagship Biotech International Private Limited, established in August 2011, is a privately held pharmaceutical company headquartered in Navi Mumbai, Maharashtra, India. The company specializes in the development, manufacturing, and marketing of a diverse range of pharmaceutical formulations, including tablets, capsules, syrups, and injections. With an authorized capital of ₹1.08 crore and a paid-up capital of ₹13.26 lakh, Flagship Biotech has demonstrated consistent growth and financial stability.

Over the years, Flagship Biotech has expanded its global footprint, operating in more than 75 countries worldwide. The company's extensive product portfolio encompasses over 700 pharmaceutical formulations across various therapeutic areas, such as oncology, anti-diabetic, cardiology, pain management, gynecology, anti-infectives, vitamins, minerals, nutrients, gastrointestinal, anti-osteoporosis, anti-malarial, immunosuppressants, anti-bacterial, anti-asthmatics, and anti-allergy.

What Does Flagship Biotech International Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Teicoplanin$250.0K

Product Portfolio — Top 4 by Export Value

Flagship Biotech International Private Limited exports 4 pharmaceutical products across 4 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Teicoplanin	Advanced Antibiotics	$250.0K	5	4.0%	2
2	Levamisole	Antimalarial & Antiparasitic	$75.0K	10	2.8%	8
3	Antitoxin	Other	$53.7K	3	0.4%	10
4	Tamoxifen	Advanced Oncology	$50.5K	5	0.3%	11

Flagship Biotech International Private Limited exports 4 pharmaceutical products across 4 therapeutic categories with a total export value of $429.3K. The top category is Advanced Antibiotics (58.2% of portfolio), followed by Antimalarial & Antiparasitic (17.5%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Flagship Biotech International Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Flagship Biotech operates state-of-the-art manufacturing facilities located in Baroda (Gujarat), Tarapur (Maharashtra), Navsari (Gujarat), Naroda (Gujarat), and Baddi (Himachal Pradesh), India. These facilities are equipped to produce a wide range of dosage forms, including solid dosage forms (tablets and capsules), liquid orals, small volume parenterals (SVP), large volume parenterals (LVP), specialty injectables, powder for injections, ointments, creams, inhalers, and herbal products. The manufacturing plants adhere to global quality standards and hold certifications from regulatory authorities such as WHO-GMP, US FDA, EU GMP, Health Canada, and PIC/S.

3Key Leadership

The leadership team at Flagship Biotech comprises experienced professionals committed to driving the company's growth and success. The key executives include:

Shailesh Dilipbhai Patel: Founder Member, Promoter, and Director.

Kedar Avinash Vidwans: Founder Member, Promoter, and Director.

Tejaswini Kedar Vidwans: Director.

Dipaben Shailesh Patel: Director.

These leaders bring a wealth of experience from their previous roles in the pharmaceutical industry, contributing to the company's strategic direction and operational excellence.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Flagship Biotech International Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Flagship Biotech has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facilities are certified by leading regulatory authorities such as WHO-GMP, US FDA, EU GMP, Health Canada, and PIC/S, ensuring compliance with stringent quality standards.

In the United States, Flagship Biotech's products are subject to approval by the FDA. The company's adherence to Good Manufacturing Practices (GMP) and other regulatory requirements facilitates market access in these regions. While specific details regarding FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed, the company's certifications indicate a commitment to meeting international regulatory standards.

2Emerging Markets

Flagship Biotech has strategically expanded its footprint in emerging markets across Africa, Latin America, and Southeast Asia. The company's extensive product portfolio is tailored to meet the diverse healthcare needs of these regions. Flagship Biotech's manufacturing facilities hold certifications from regulatory authorities such as WHO-GMP, Health Canada, and PIC/S, which are essential for market access in these regions.

The company's commitment to quality and regulatory compliance has enabled it to establish a strong presence in these emerging markets, contributing to improved healthcare access and outcomes.

Flagship Biotech International Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Flagship Biotech's manufacturing facilities are certified by the US FDA, indicating compliance with the agency's stringent quality standards. While specific details regarding FDA facility registrations, approved ANDAs, DMF filings, and inspection history are not publicly disclosed, the company's adherence to Good Manufacturing Practices (GMP) and other regulatory requirements facilitates market access in the United States.

2WHO & EU GMP

Flagship Biotech's manufacturing facilities hold certifications from the World Health Organization's Good Manufacturing Practices (WHO-GMP) and the European Union's Good Manufacturing Practices (EU GMP). These certifications attest to the company's commitment to maintaining high-quality standards in its manufacturing processes.

3CDSCO & Indian Regulatory

Flagship Biotech's manufacturing facilities are approved by the Central Drugs Standard Control Organisation (CDSCO) in India, ensuring compliance with national regulatory standards. The company's adherence to CDSCO guidelines and other state drug controller approvals underscores its commitment to maintaining high-quality standards in its manufacturing processes.

Flagship Biotech International Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Flagship Biotech operates in a competitive landscape with several key players in the pharmaceutical industry. While specific market share data is not publicly disclosed, the company's extensive product portfolio and global presence position it as a significant competitor in various therapeutic categories. The company's adherence to international quality standards and regulatory compliance further enhances its competitive edge.

2Key Differentiators

Flagship Biotech's key differentiators include its extensive product portfolio, encompassing over 700 pharmaceutical formulations across various therapeutic areas. The company's manufacturing facilities are certified by leading regulatory authorities, ensuring compliance with international quality standards. Additionally, Flagship Biotech's strategic expansion into over 75 countries demonstrates its commitment to global healthcare access.

3Strategic Position

Flagship Biotech's strategic direction focuses on expanding its global footprint while maintaining high-quality standards and regulatory compliance. The company's diverse product portfolio and presence in over 75 countries position it to leverage growth opportunities across different regions. Future outlooks suggest continued focus on innovation, market expansion, and strengthening partnerships to enhance its position in the global pharmaceutical industry.

Buyer Due Diligence Brief — Evaluating Flagship Biotech International Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Flagship Biotech has demonstrated a strong track record in pharmaceutical manufacturing, with an extensive product portfolio and certifications from leading regulatory authorities. The company's manufacturing facilities adhere to international quality standards, ensuring the reliability and consistency of its products. The company's global presence and adherence to regulatory requirements further underscore its reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Approval: Confirm that the manufacturing facility is registered with the US FDA.

WHO-GMP Certification: Verify that the manufacturing facility holds WHO-GMP certification.

EU GMP Certification: Ensure that the manufacturing facility is certified under EU GMP standards.

Frequently Asked Questions — Flagship Biotech International Private Limited

How many pharmaceutical products does Flagship Biotech International Private Limited export from India?

Flagship Biotech International Private Limited exports 4 pharmaceutical products across 4 therapeutic categories. The top exports are Teicoplanin ($250.0K), Levamisole ($75.0K), Antitoxin ($53.7K), Tamoxifen ($50.5K). Total export value is $429.3K.

What is Flagship Biotech International Private Limited's total pharmaceutical export value?

Flagship Biotech International Private Limited's total pharmaceutical export value is $429.3K, based on 23 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Flagship Biotech International Private Limited cover?

Flagship Biotech International Private Limited exports across 4 therapeutic categories. The largest are Advanced Antibiotics (58.2%, 1 products), Antimalarial & Antiparasitic (17.5%, 1 products), Other (12.5%, 1 products).

Get Full Flagship Biotech International Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.